Women’s Health¶
Chapter 410 | Part 12: Endocrinology and Metabolism
KEY CLINICAL POINTS¶
- Women face unique cardiovascular risks, including higher mortality from CVD in older age and distinct symptom presentations (e.g., fatigue, dyspnea).
- Estrogen and androgen imbalances contribute to sex-specific differences in disease susceptibility, including higher AD risk in women and CVD risk in men.
- Hormone therapy (HT) has limited efficacy for CVD prevention and carries risks of stroke and thromboembolism, with benefits primarily for vasomotor symptoms.
- Obesity prevalence is higher in non-Hispanic Black women, with abdominal obesity linked to increased CVD and DM risk.
- Sex differences in immune responses and drug metabolism require tailored approaches to autoimmune disorders and pharmacotherapy.
1. DEFINITION & OVERVIEW¶
Women’s health encompasses biologic, psychosocial, and cultural factors influencing health outcomes. It includes unique risks for CVD, autoimmune disorders, reproductive health, and sex hormone-related conditions. Sex differences in disease prevalence, pathophysiology, and treatment responses are central to clinical management.
Table 410-1: Leading Causes of Death in U.S. Women vs. Men (2020)¶
| Cause | Women (%) | Men (%) |
|---|---|---|
| Heart Disease | 20% | 22% |
| Cancer | 18% | 18% |
| COVID-19 | 6% | 3.9% |
| Chronic Lower Respiratory Disease | 5% | 4.1% |
| Stroke/AD | 10% | 2.3% |
| Accidents | 4% | 10.9% |
Table 410-2: Traditional and Nontraditional CVD Risk Factors in Women¶
| Risk Factor | Women | Men |
|---|---|---|
| Hypertension | 3 | 3 |
| Hyperlipidemia | 3 | 3 |
| DM | 3 | 3 |
| Obesity (abdominal) | 3 | 3 |
| Risk Factor | Women | Men |
|---|---|---|
| Smoking | 3 | 3 |
| Low HDL | 3 | 3 |
| Family History | 3 | 3 |
| Pregnancy Complications | 3 | 7 |
| RA/RAAS Dysregulation | 3 | 3 |
| Psychosocial Stress | 3 | 3 |
1.1 Sex Differences in Health¶
Sex differences refer to biologic variations due to sex chromosomes and hormones, while gender differences relate to psychosocial factors. Women face higher risks for CVD mortality, autoimmune diseases, and certain cancers, while men have higher rates of suicide and accidents. These differences are influenced by hormonal, genetic, and environmental factors.
1.2 Key Clinical Focus Areas¶
Key areas include cardiovascular disease (CVD), diabetes mellitus (DM), osteoporosis, reproductive health, autoimmune disorders, and sex hormone-related conditions. Women’s health also addresses disparities in maternal mortality and access to reproductive care.
2. EPIDEMIOLOGY¶
Women live 5.9 years longer than men (79.1 vs. 73.2 years in 2021). CVD remains the leading cause of death, with higher mortality in men but distinct symptom patterns in women. Maternal mortality rates are higher in the U.S. compared to other industrialized nations, with restricted abortion access linked to increased maternal mortality (62% higher in restrictive states).
2.1 Disease Prevalence¶
CVD: Women have higher rates of atypical symptoms (fatigue, dyspnea) and lower survival after MI. Alzheimer’s disease (AD): Affects twice as many women as men, with estrogen deficiency linked to cognitive decline. Osteoporosis: Fivefold more common in postmenopausal women.
2.2 Demographics¶
Non-Hispanic Black women have highest obesity prevalence (57.9%), while Hispanic and Asian women have lower rates. Menopause occurs earlier in Hispanic/African-American women and those with lower socioeconomic status.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Sex hormone imbalances (estrogen, androgen) influence CVD, bone metabolism, and immune function. Estrogen protects against CVD but increases breast cancer risk. Androgen deficiency contributes to osteoporosis and metabolic syndrome. Genetic factors (e.g., APOE ε 4 allele) and sex-specific immune responses (e.g., higher autoimmune disease incidence) drive sex differences.
3.1 Hormonal Mechanisms¶
Estrogen: Enhances HDL, reduces LDL, and protects against CVD. Androgen deficiency: Linked to osteoporosis and metabolic syndrome. Sex hormone fluctuations during the menstrual cycle affect immune responses and mood.
4. CLINICAL FEATURES¶
Women present with atypical CVD symptoms (fatigue, dyspnea). Hypertension is more common after age 60. Diabetes mellitus (DM) has higher CVD mortality risk in women. Autoimmune disorders (e.g., SLE, RA) are more prevalent in women. Osteoporosis presents with increased fracture risk, particularly in postmenopausal women.
4.1 CVD Presentation¶
Women more likely to present with fatigue, dyspnea, and non-chest-pain symptoms. Higher risk of cardiac arrest and cardiogenic shock compared to men. Atypical symptoms contribute to delayed diagnosis.
4.2 Hormonal Disorders¶
Estrogen deficiency: Causes vasomotor symptoms, osteoporosis, and sexual dysfunction. Androgen deficiency: Linked to reduced libido and metabolic syndrome. Hormonal imbalances also affect mental health (e.g., depression, anxiety).
5. DIFFERENTIAL DIAGNOSIS¶
For CVD: Atypical symptoms vs. non-cardiac causes (e.g., anemia, thyroid dysfunction). For sexual dysfunction: Hormonal imbalances vs. psychological factors. For autoimmune disorders: Differentiate between sex-specific conditions (e.g., SLE) and other systemic diseases.
5.1 CVD Mimics¶
Anemia, hypothyroidism, and pulmonary embolism may mimic CVD symptoms. Psychosocial stress and depression contribute to atypical presentations.
5.2 Hormonal Disorders¶
Differentiate between estrogen deficiency (vasomotor symptoms, osteoporosis) and androgen deficiency (libido loss, metabolic syndrome). Consider pregnancy-related complications (e.g., preeclampsia) in women with CVD risk.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic criteria include ECG for CVD, HbA1c for DM, and bone density scans for osteoporosis. Hormonal assays (estradiol, testosterone) assess endocrine status. Imaging (e.g., coronary angiography) evaluates CVD. Genetic testing (e.g., APOE ε 4) identifies AD risk.
6.1 CVD Evaluation¶
ECG, troponin, and coronary angiography. Women may require more extensive testing due to atypical presentations. Stress testing is less effective in women with comorbidities.
6.2 Hormonal Assessment¶
Serum estradiol, testosterone, and SHBG levels. Pelvic ultrasound for ovarian function. Bone density scan (DEXA) for osteoporosis risk.
7. MANAGEMENT & TREATMENT¶
Hormone therapy (HT) for menopausal symptoms with caution due to CVD risks. Pharmacologic agents for CVD (e.g., statins, ACE inhibitors), DM (metformin), and osteoporosis (bisphosphonates). Lifestyle modifications (diet, exercise) are critical for obesity and metabolic syndrome.
7.1 Hormone Therapy¶
Estrogen/progestin for menopausal symptoms, with risks of stroke and thromboembolism. Avoid in women with breast cancer history. Low-dose estrogen for vaginal atrophy. Testosterone therapy for androgen deficiency.
7.2 CVD Management¶
Antihypertensives (ACE inhibitors, calcium channel blockers), statins, and lifestyle changes. Women with MI require more aggressive risk factor modification due to higher mortality risk.
8. PROGNOSIS & COMPLICATIONS¶
Women have higher CVD mortality in older age but better survival after MI with improved risk factor management. AD risk is doubled due to estrogen deficiency. Osteoporotic fractures increase morbidity and mortality in elderly women. Maternal mortality remains a significant public health issue.
8.1 CVD Outcomes¶
Women have higher rates of cardiac arrest and cardiogenic shock but improved survival with early intervention. Atypical symptoms delay diagnosis, worsening outcomes.
8.2 Long-Term Risks¶
Postmenopausal women face increased CVD, osteoporosis, and AD risk. Obesity-related cancers (breast, endometrial) are more common in women with metabolic syndrome.
9. SPECIAL CONSIDERATIONS¶
Pregnancy-related complications (e.g., preeclampsia) increase CVD risk. Maternal mortality disparities persist in the U.S. Hormone therapy requires careful risk-benefit analysis. Sex-specific pharmacokinetics affect drug efficacy and side effects.
9.1 Pregnancy and CVD¶
Pregnancy increases CVD risk due to hemodynamic changes. Preeclampsia and gestational diabetes are linked to chronic hypertension and DM. Women with DM have sixfold higher CVD mortality.
9.2 Hormone Therapy¶
HT carries risks of breast cancer, stroke, and thromboembolism. Avoid in women with contraindications. Testosterone therapy for androgen deficiency requires monitoring for cardiovascular effects.
10. KEY POINTS & CLINICAL PEARLS¶
Women face unique CVD risks due to hormonal, genetic, and psychosocial factors. Hormone therapy should be individualized with caution. Atypical CVD presentations in women require thorough evaluation. Obesity and metabolic syndrome are major contributors to CVD and DM in women. Sex-specific pharmacokinetics and immune responses necessitate tailored treatment approaches.